Ajanta Pharma’s subsidiary - Ajanta Pharma USA Inc., has launched Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market. The company offers Montelukast Granules in cartons containing 30 individual sachets.
The approval and launch of the Montelukast Granules is part of an ever-growing portfolio that Ajanta Pharma has developed for the US market. The United States Food & Drug Administration (USFDA) till date has granted five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the USFDA.
Ajanta Pharma is a fully-integrated pharmaceutical company employing over 6,000 employees, engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries.
